Drug intelligence / Profile preview

PDI-192

Development stage: Phase 2
Lead developer: PreCision Dermatology
Modality: Small Molecules
Administration: Topical

Overview

PDI-192 is a small molecule drug developed for the treatment of mild to moderate atopic dermatitis, primarily in pediatric and adolescent populations. The drug was originally developed by PreCision Dermatology and later became part of Bausch Health Americas (formerly Valeant Pharmaceuticals) following acquisition. Its mechanism of action remains undefined or unreported in public sources, and it does not have an orphan drug designation. Clinical development reached Phase 2 trials but no further progress or approval has been reported as of the latest updates[1][2][3].

Other names: PDI 192PDI192PDI-192

Beyond the preview

Go deeper on PDI-192.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDI-192.

Explore the full profile